They do have other potential blockbusters in the pipeline such as Garadacimab (CSL312), a novel, fully-human monoclonal antibody that inhibits activated factor XII (FXIIa), for the prevention of hereditary angioedema attacks. Phase III trials complete. Forecast to add $50 to share price
CSL112, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$285.10 |
Change
-6.060(2.08%) |
Mkt cap ! $138.0B | |||
| Open | High | Low | Value | Volume |
| $289.85 | $291.99 | $285.10 | $215.2M | 748.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2976 | $285.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $286.53 | 75 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |